12/1 Business Wire Health: Mental Health News

Please add updates@feedmyinbox.com to your address book to make sure you receive these messages in the future. Business Wire Health: Mental Health News Dec. 2 Rally: Lanterman Psychiatric Technicians Still Working for No Pay November 30, 2009 at 5:59 pm --(BUSINESS WIRE)--CAPT: WHEN:   Wednesday, December 2; 10 a.m. – 2 p.m.   WHERE: Lanterman Developmental Center, 3530 Pomona Blvd., Pomona; Diamond Bar Blvd. entrance.   WHO: Lanterman Developmental Center employee members of the California Association of Psychiatric Technicians.   VISUALS: Dozens of Psychiatric Technicians and allied state workers wearing union T-shirts and waving picket signs.   WHY: The California Association of Psychiatric Technicians is conti Media Files ViewMedia?mgid=190569&vid=2 (2 KB) Titan Receives Notice of Allowance for Probuphine® Patent Application in the Treatment of Opiate Addiction November 30, 2009 at 1:57 pm SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Titan Pharmaceuticals, Inc (Pink Sheets:TTNP) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Titan’s United States patent application directed to the use of Probuphine for the treatment of opiate addiction. The patent application is U.S. Application No. 10/453,377 filed June 2, 2003 titled “Implantable polymeric device for sustained release of buprenorphine”. The newly Media Files ViewMedia?mgid=206544&vid=2 (2 KB) American Telemedicine Association: Guidelines Approved for Delivery of Remote Mental Health Services November 30, 2009 at 11:37 am WASHINGTON--(BUSINESS WIRE)--The American Telemedicine Association (ATA) announced the availability of formal practice guidelines for the use of videoconferencing for the delivery of mental health services. These guidelines are designed to form the standard of care for such services and will be the basis for the development and practice of uniform, effective, safe and sustainable telemental health practices. They will serve as both an operational reference and an educational tool to aid in provi Research and Markets: Insomnia or Sleep Disorders Therapy Area Pipeline Report Combines Details on the Top 20 Companies with Products in the Early and Late Stage of Development November 30, 2009 at 10:45 am DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/30d3e4/insomnia_or_sleep) has announced the addition of the "Insomnia or Sleep Disorders Therapy Area Pipeline Report" report to their offering. Life Science Analytics, Insomnia or Sleep Disorders Therapy Area Pipeline Report contains detailed information on the insomnia or sleep disorders drug pipeline. This report provides insight into the pipeline status of insomnia or sleep disorders drugs by company an Three Lou Gehrig's Disease (ALS) Organizations Grant Funding for Research Collaboration Between RXi Pharmaceuticals and UMass Medical School November 30, 2009 at 7:00 am WORCESTER, Mass.--(BUSINESS WIRE)--Three prominent philanthropic organizations – The Angel Fund, The ALS Therapy Alliance and Project ALS -- dedicated to finding a treatment for amyotrophic lateral sclerosis (ALS) have financed a new collaboration between one of the world’s leading ALS researchers and RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi). Media Files ViewMedia?mgid=124005&vid=2 (2 KB)   This email was sent to billionlys.asdf1234@blogger.com.  Manage Your Account Don't want to receive this feed any longer? Unsubscribe here.